ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3c.org/TR/1999/REC-html401-19991224/loose.dtd"> <HTML xmlns="http://www.w3.org/1999/xhtml"><HEAD><TITLE>What is Neuromathix Software NeuroTech Research</TITLE><LINK rel=stylesheet type=text/css href="../Sites-Local/GettingStarted/1-Design/Assets/CSS/divs.css"> <META content="text/html; charset=unicode" http-equiv=Content-Type> <SCRIPT language=JavaScript type=text/JavaScript> <!-- function MM_preloadImages() { //v3.0 var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array(); var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++) if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}} } function MM_findObj(n, d) { //v4.01 var p,i,x; if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) { d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);} if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n]; for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document); if(!x && d.getElementById) x=d.getElementById(n); return x; } function MM_nbGroup(event, grpName) { //v6.0 var i,img,nbArr,args=MM_nbGroup.arguments; if (event == "init" && args.length > 2) { if ((img = MM_findObj(args[2])) != null && !img.MM_init) { img.MM_init = true; img.MM_up = args[3]; img.MM_dn = img.src; if ((nbArr = document[grpName]) == null) nbArr = document[grpName] = new Array(); nbArr[nbArr.length] = img; for (i=4; i < args.length-1; i+=2) if ((img = MM_findObj(args[i])) != null) { if (!img.MM_up) img.MM_up = img.src; img.src = img.MM_dn = args[i+1]; nbArr[nbArr.length] = img; } } } else if (event == "over") { document.MM_nbOver = nbArr = new Array(); for (i=1; i < args.length-1; i+=3) if ((img = MM_findObj(args[i])) != null) { if (!img.MM_up) img.MM_up = img.src; img.src = (img.MM_dn && args[i+2]) ? args[i+2] : ((args[i+1])? args[i+1] : img.MM_up); nbArr[nbArr.length] = img; } } else if (event == "out" ) { for (i=0; i < document.MM_nbOver.length; i++) { img = document.MM_nbOver[i]; img.src = (img.MM_dn) ? img.MM_dn : img.MM_up; } } else if (event == "down") { nbArr = document[grpName]; if (nbArr) for (i=0; i < nbArr.length; i++) { img=nbArr[i]; img.src = img.MM_up; img.MM_dn = 0; } document[grpName] = nbArr = new Array(); for (i=2; i < args.length-1; i+=2) if ((img = MM_findObj(args[i])) != null) { if (!img.MM_up) img.MM_up = img.src; img.src = img.MM_dn = (args[i+1])? args[i+1] : img.MM_up; nbArr[nbArr.length] = img; } } } //--> </SCRIPT> <STYLE type=text/css> <!-- .style1 {color: #FFFFFF} .style2 {color: #0000FF; } --> </STYLE> <META name=GENERATOR content="MSHTML 8.00.6001.18852"></HEAD> <BODY onload="MM_preloadImages('resources/home_gold.jpg','resources/Team_gold.jpg','resources/Contact_gold.jpg')"> <DIV id=row1> <DIV class=navbar> <DIV class=navbar> <TABLE border=0 cellSpacing=0 cellPadding=0> <TBODY> <TR> <TD><A onmouseover="MM_nbGroup('over','Home','resources/home_gold.jpg','',1)" onmouseout="MM_nbGroup('out')" onclick="MM_nbGroup('down','group1','Home','',1)" href="index.html" target=_top><IMG id=Home border=0 name=Home alt=Home src="resources/Home.jpg" width=180 onload="" height=53></A></TD> <TD><A onmouseover="MM_nbGroup('over','Team','resources/Team_gold.jpg','',1)" onmouseout="MM_nbGroup('out')" onclick="MM_nbGroup('down','group1','Team','',1)" href="team.html" target=_top><IMG id=Team border=0 name=Team alt="" src="resources/Team.jpg" width=180 onload="" height=53></A></TD> <TD><A onmouseover="MM_nbGroup('over','Contact','resources/Contact_gold.jpg','',1)" onmouseout="MM_nbGroup('out')" onclick="MM_nbGroup('down','group1','Contact','',1)" href="contact.html" target=_top><IMG id=Contact border=0 name=Contact alt="" src="resources/Contact.jpg" width=180 onload="" height=53></A></TD></TR></TBODY></TABLE> <H1>Neuromathix Software</H1></DIV></DIV></DIV> <DIV id=main> <DIV id=col2> <DIV id=feature> <P align=center><IMG src="resources/neuromathix_logo.jpg" width=272 height=390></P> <P align=center>&nbsp;</P> <H1>What is It? <P></P></H1> <P align=justify><FONT size=4><STRONG>Computer software, to run as a cloud computing service</STRONG>, enabling patient-specific parameters for complex models of drug-disease interactions to be reconstructed from appropriate fragments of time-series measurements for individual patients. This means that modern mathematical control methods (sourced from aerospace and robotics, hitherto unused in a medical context) can then be deployed in a patient-specific way, to enhance the effectiveness of medication and reduce side-effects. These methods work for complex systems, where the conventional statistical methods employed by Pharma companies have difficulty giving useful results. <BR><BR> Validated using <EM>in silico</EM> simulations, this software is expected to be most relevant for enhancing medication in chronic or degenerative diseases: immediate&nbsp;medical&nbsp;tasks&nbsp;include type-1 diabetes, haemodynamics and some forms of cancer.&nbsp;The&nbsp;objective is&nbsp;to improve therapeutic outcomes for patients suffering from these diseases.<BR><BR><BR>This technology&nbsp;also has relevance in&nbsp;helping to reduce the current Phase II bottleneck in clinical trials, by improving&nbsp;calculation of&nbsp;ADME parameters and&nbsp;generating mathematical strategies for improved drug administration. This will enhance the potential effectiveness and reduce&nbsp;the risk of&nbsp;side-effects&nbsp;of a good drug candidate, and hence improve its success probabilities.&nbsp;<BR><BR><BR><BR><FONT color=#ff0000><FONT color=#004080><STRONG>Pharmacokinetics </STRONG>(<STRONG>PK</STRONG>): is the maths of&nbsp;how a biological system (say, a human body) affects a drug. <BR><STRONG>Pharmacodynamics</STRONG> (<STRONG>PD</STRONG>): is the maths of how a drug affects a biological system.<BR><BR>Successful medication of a patient involves understanding both the PK and PD of drug-disease interactions. In particular&nbsp;a drug's&nbsp;<STRONG>ADME</STRONG> (<STRONG>absorption</STRONG>, <STRONG>distribution</STRONG>, <STRONG>metabolism</STRONG> and <STRONG>excretion</STRONG>) parameters are extremely useful to know accurately, for optimised drug dosage.&nbsp;But these are patient-specific, and realistic PK and PD models can become extremely complex.&nbsp;There quickly comes a&nbsp;level of complexity&nbsp;where traditional population-based statistical methods fail. This is where the Neuromathix software steps in.</FONT>&nbsp;&nbsp;<BR></FONT><BR><BR><BR><STRONG><FONT size=6>Why?<BR></FONT></STRONG><BR>Personalised medication, to reduce unpleasant or toxic side-effects or to optimise the effectiveness of a drug,&nbsp;is the "Holy Grail" of medical and pharmaceutical research. But this research is dominated by an assumption: that the next huge step forward in patient-specific medication has to await genomic technologies, to analyse a patient's genes. This reflects the current reliance of the medical and pharmaceutical industries on traditional statistical methods, plus new developments in genetics/genomics.</FONT></P> <P align=justify><FONT size=4>In reality, sophisticated software already developed using other forms of modern mathematics, when combined with appropriate imaging, measurement and drug delivery technologies, can deliver&nbsp;improved patient-specific medication control in other ways. (And once genomics-based solutions are available, this synergy of technologies will <EM>still</EM> be needed, especially in the handling of physiological issues not reflected by the patient's DNA... like large-scale damage to membranes and organs, or disease-induced changes to drug uptake or elimination.) This sophisticated software is called the <STRONG>Neuromathix</STRONG> suite.</FONT></P> <P><FONT size=4>It has two components:</FONT></P> <UL> <LI><FONT size=4>The <STRONG>Neuromathix Identifier</STRONG>: is software able to estimate hidden patient-specific biological parameters governing drug uptake, tranport, metabolism and elimination, reconstructed mathematically using high-performance computing, from a suitable partial fragment of time-series data matched to a drug input;</FONT> </LI></UL> <P><FONT size=4></FONT>&nbsp;</P> <UL> <LI><FONT size=4>The </FONT><FONT size=4><STRONG>Neuromathix Control Set</STRONG>: building on the Identifier, it employs sophisticated control algorithms to obtain a medication program, delivering enhanced control for specified drugs on an Identified human patient, animal subject or tissue sample.</FONT> </LI></UL> <P><FONT size=4></FONT>&nbsp;</P> <P align=justify><FONT size=4>The combination of the two packages is aimed at enhancing drug&nbsp;effectiveness and reducing waste across the entire drug lifecycle, from drug R&amp;D and trialling through to clinical deployment and even post-patent re-bundling. </FONT></P> <P align=justify><FONT size=4>By moving to advanced computational methods, the costs of the current waste plus delay bottlenecks inherent in drug discovery and clinical trialling appears reducible by millions of dollars, based on simulation studies. This appears especially relevant in Phase II trials.</FONT></P> <P align=justify><FONT size=4>The technology has been validated in computer simulations, with the <SPAN class=italictext><EM>in silico </EM></SPAN>results to be published.</FONT></P> <P align=justify><FONT size=4>Strong potential exists for partnering synergies with international pharma and medical device companies, as well as&nbsp;non-invasive imaging and sampling technologies and drug delivery hardware manufacturers. Partnerships with relevant international companies are now being sought, for pilot demonstration trials.<BR><BR><BR><BR>NeuroTech Research Pty Ltd has been awarded (October 2009) <A href="http://www.health.qld.gov.au/ohmr/html/rpu/med_dev_fin_inc_pro.asp" target=_blank>Medical Devices Financial Incentive Program</A>&nbsp;funding from Queensland Health, to construct an advanced prototype of its Neuromathix application for type-1 diabetes, to run on a high-performance computing platform. It has also been awarded (2010) Proof of Concept funding from the Department of Employment, Economic Development and Innovation. <BR><BR> </FONT><FONT size=4 face=Times>NeuroTech Research Pty Ltd is a past awardee of the Queensland Government's Innovation Start-Up Scheme (ISUS) grant.</FONT></P> <P align=justify>&nbsp;</P> <P align=justify><FONT size=4>PRESS RELEASE, December 2011: Dr Jenny Gunton, of the <a href="http://www.garvan.org.au" target="_blank">Garvan Institute of Medical Research</a>, and Dr Nigel Greenwood, of Neuromathix (NeuroTech Research Pty Ltd), have been awarded an Innovative grant by the <a href="http://www.jdrf.org" target="_blank">JDRF</a> in New York. Dr Greenwood is a mathematician specialising in artificial intelligence, while Dr Gunton is Head of the Diabetes and Transcription Factors Group at the Garvan. The project will use new computer software (the "Neuromathix algorithms"), able to reconstruct complex personalised medical models from limited information, to demonstrate how devices like insulin pumps can be modified with "machine-intelligent" software to improve insulin dosing for patients with type 1 diabetes. </P> </DIV></DIV> <DIV id=col1> <H3 class=style1 align=center><IMG src="resources/neuromathix_logo_small.jpg" width=100 height=143></H3> <H3 class=style2 align=center>NeuroTech Research Pty Ltd </H3> <P><SPAN class=style2 align=center>Copyright &copy;2009-2011 NeuroTech Research Pty. Ltd., all rights reserved. </SPAN></P> <P>&nbsp;</P> <P><A href="http://www.qctn.com.au" target=_blank><IMG alt=QCTN src="resources/QCTNcol.jpg" width=128 height=65></A></A></P> <P>NeuroTech Research is a proud member of the <A href="http://www.qctn.com.au" target=_blank>Queensland Clinical Trials Network</A>. </P> <P>The company is also a proud member of <a href="http://www.gpucomputing.net" title="GPUComputing" target="_blank">GPUComputing.net</a>.</P> <P>&nbsp;</P> </DIV></DIV></BODY></HTML>